Federal opportunity Burleson Research Technologies recently secured a federal contract with the Environmental Protection Agency for mouse assays to assess lead bioavailability in soil and dust, signaling a pathway for near-term government project opportunities and potential expansion into federal procurement channels.

NAMs leadership BRT is an early adopter and provider of new approach methodologies (NAMs) such as DPRA, KeratinoSens, h-CLAT, and GARD, positioning the company to win biotech and chemical clients seeking advanced in vitro immunotoxicology and alternative method testing.

Biotech partnerships The firm already collaborates with biotechnology, pharmaceutical, and chemical companies, creating a ready channel to cross-sell expanded immunotoxicology services, immune safety testing, and preclinical in vivo/in vitro assessments.

Growing footprint With a focus on fit-for-purpose study designs and high-quality, reproducible results, BRT can scale services to attract mid-sized sponsors seeking reliable immunotoxicology data without engaging large CROs, offering a tailored partner for niche projects.

Market expansion BRT’s expansion into environmental and health-facing testing (e.g., lead bioavailability in soils/dust) suggests cross-selling opportunities to clients needing environmental risk assessment data, regulatory-compliant toxicology, and safety profiling across product lifecycles.